Status:
ACTIVE_NOT_RECRUITING
Link Between Reduction of Suicide Ideation by Esketamine in Add-On and Initial Levels of Psychological Pain and Anhedonia
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Depression - Major Depressive Disorder
Depression Disorder
Eligibility:
All Genders
18-64 years
Brief Summary
This study is looking at how intranasal esketamine (a nasal spray) can help reduce suicidal thoughts in patients with severe depression who are experiencing suicidal thoughts. Suicidal depression is a...
Eligibility Criteria
Inclusion
- patients who participated in the ASPIRE I (NCT03039192) and ASPIRE II (NCT03097133)
Exclusion
- Not applicable
Key Trial Info
Start Date :
November 24 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 24 2025
Estimated Enrollment :
456 Patients enrolled
Trial Details
Trial ID
NCT07199179
Start Date
November 24 2024
End Date
November 24 2025
Last Update
September 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Montpellier
Montpellier, France